In a study from the University of Pittsburgh, scientists developed a test to detect a novel marker of Alzheimer’s disease neurodegeneration in a blood sample.
The biomarker, called brain-derived tau, or BD-tau, outperforms current blood diagnostic tests used to detect Alzheimer’s-related neurodegeneration clinically.
It is specific to Alzheimer’s disease and correlates well with Alzheimer’s neurodegeneration biomarkers in the cerebrospinal fluid (CSF).
At present, diagnosing Alzheimer’s disease requires neuroimaging.
Those tests are expensive and take a long time to schedule, and a lot of patients, even in the U.S., don’t have access to MRI and PET scanners. Accessibility is a major issue.
The team says the most important utility of blood biomarkers is to make people’s lives better and to improve clinical confidence and risk prediction in Alzheimer’s disease diagnosis.
In the study, they developed a technique to selectively detect BD-tau while avoiding free-floating “big tau” proteins produced by cells outside the brain.
To do that, they designed a special antibody that selectively binds to BD-tau, making it easily detectible in the blood.
They validated their assay across over 600 patient samples from five independent cohorts, including those from patients whose Alzheimer’s disease diagnosis was confirmed after their deaths, as well as from patients with memory deficiencies indicative of early-stage Alzheimer’s.
The tests showed that levels of BD-tau detected in blood samples of Alzheimer’s disease patients using the new assay matched with levels of tau in the CSF and reliably distinguished Alzheimer’s from other neurodegenerative diseases.
Levels of BD-tau also correlated with the severity of amyloid plaques and tau tangles in the brain tissue confirmed via brain autopsy analyses.
Scientists hope that monitoring blood levels of BD-tau could improve clinical trial design and facilitate screening and enrollment of patients from populations that historically haven’t been included in research cohorts.
The team is planning to conduct large-scale clinical validation of blood BD-tau in a wide range of research groups, including those that recruit participants from diverse racial and ethnic backgrounds, from memory clinics, and from the community.
If you care about Alzheimer’s, please read studies about diabetes drug that may also help to prevent Alzheimer’s disease, and coconut oil could help improve cognitive function in Alzheimer’s disease.
For more information about brain health, please see recent studies about antioxidants that could help reduce dementia risk, and Vitamin B supplements could help reduce dementia risk.
The study was conducted by Thomas Karikari et al and published in Brain.
Copyright © 2022 Knowridge Science Report. All rights reserved.
